Breakthrough Study Reveals Simple Blood Test Could Predict Rapid Alzheimer’s Decline

In a significant development for Alzheimer’s research and patient care, new study results presented this week at the 11th European Academy of Neurology (EAN) Congress in Helsinki, Finland, indicate that a common blood test for insulin resistance can accurately predict rapid cognitive decline in individuals with early-stage Alzheimer’s disease.

The findings, unveiled at the prestigious congress which concluded on June 24th, highlight the increasingly recognized link between metabolic dysfunction, particularly insulin resistance, and the progression of Alzheimer’s. While insulin resistance has been implicated in the disease’s development, its precise influence on the rate of cognitive deterioration has remained less clear until now. This breakthrough offers a much-needed accessible marker to forecast disease progression, empowering clinicians to tailor interventions and support families in their long-term planning.

Conducted as a retrospective single-centre study at the University of Brescia, researchers analyzed data from 315 non-diabetic patients suffering from various neurodegenerative conditions. This group included 210 individuals with cerebrospinal fluid-confirmed Alzheimer’s disease and 115 with other neurological disorders. All participants underwent initial clinical and biochemical assessments, including the calculation of the triglyceride-glucose (TyG) index – a widely accepted marker for insulin resistance – followed by at least six months of clinical follow-up.

Patients were categorized into tertiles based on their TyG index. A crucial discovery emerged from the subgroup of 161 patients diagnosed with mild cognitive impairment due to Alzheimer’s disease: those in the highest TyG tertile were over four times more likely to experience rapid cognitive decline. This rapid decline was defined as a loss of more than 2.5 points per year on the Mini Mental State Examination. Notably, this strong association was specific to Alzheimer’s patients and was not observed in individuals with other neurodegenerative diseases.

The study also noted that high TyG in Alzheimer’s patients correlated with increased cardiovascular risk and markers of blood-brain barrier disruption, though it did not interact with the APOE ε4 genotype. These results underscore that insulin resistance, as measured by the TyG index, acts as a disease-specific predictor of cognitive decline in early Alzheimer’s, setting it apart from other neurodegenerative conditions.

For clinical practice, these findings are immensely promising. A readily available and low-cost blood test like the TyG index could soon become a vital tool for identifying Alzheimer’s patients at a higher risk of accelerated deterioration. This could enable more targeted and timely use of lifestyle interventions, metabolic therapies, or even expedite inclusion in crucial clinical trials for disease-modifying treatments, ultimately improving patient outcomes and quality of life.

阅读中文版 (Read Chinese Version)

Disclaimer: This content is aggregated from public sources online. Please verify information independently. If you believe your rights have been infringed, contact us for removal.